公开(公告)号：US20240141296A1

公开(公告)日：2024-05-02

申请号：US18278806

申请日：2022-02-24

申请人： SWEDISH STROMABIO AB

发明人： Karl-Henrik Grinnemo ,  Oscar Simonson ,  Sergey Rodin

IPC分类号： C12N5/0775

CPC分类号： C12N5/0662 ,  C12N2501/599

摘要： The present invention relates to methods for culturing and isolating cells such as multipotent stem cells or multipotent progenitor cells. The methods of the invention comprise using the human CD105 polypeptide as a cell culture substrate. The cells obtained according to the methods of the invention are capable of forming colony forming unit-fibroblasts (CFU-Fs). Cell lines comprising such cells are useful for the treatment of medical conditions, such as acute respiratory distress syndrome (ARDS).

公开(公告)号：US20240124895A1

公开(公告)日：2024-04-18

申请号：US18074781

申请日：2022-12-05

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Daniel P. Dever ,  Rasmus O. Bak ,  Ayal Hendel ,  Waracharee Srifa ,  Matthew H. Porteus

IPC分类号： C12N15/90 ,  A61K31/7115 ,  A61K35/28 ,  A61K48/00 ,  A61P7/00 ,  C07K14/805 ,  C12N5/0775 ,  C12N5/0781 ,  C12N5/0783 ,  C12N5/0789 ,  C12N9/22 ,  C12N15/113 ,  C12N15/85 ,  C12N15/864

CPC分类号： C12N15/907 ,  A61K31/7115 ,  A61K35/28 ,  A61K48/00 ,  A61P7/00 ,  C07K14/805 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0647 ,  C12N5/0665 ,  C12N9/22 ,  C12N15/113 ,  C12N15/85 ,  C12N15/8645 ,  C12N2310/20 ,  C12N2310/311 ,  C12N2310/3125 ,  C12N2310/313 ,  C12N2750/14143

摘要： In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.

公开(公告)号：US11959104B2

公开(公告)日：2024-04-16

申请号：US17712785

申请日：2022-04-04

申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER

发明人： Lorenz Studer ,  Bastian Zimmer ,  Jason Tchieu

IPC分类号： C12N5/00 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/0775 ,  C12N5/079 ,  C12N5/0793 ,  A61K35/12

CPC分类号： C12N5/0667 ,  C12N5/0018 ,  C12N5/0606 ,  C12N5/0618 ,  C12N5/0619 ,  C12N5/0696 ,  A61K35/12 ,  C12N2501/01 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/03 ,  C12N2506/04 ,  C12N2510/00 ,  C12N2533/52

摘要： The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative and pituitary disorders.

公开(公告)号：US20240117316A1

公开(公告)日：2024-04-11

申请号：US18376566

申请日：2023-10-04

申请人： GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.

发明人： Yu-Chen Tsai ,  Ming-Hsi Chuang ,  Po-Cheng Lin

IPC分类号： C12N5/0775 ,  A61K35/28

CPC分类号： C12N5/0665 ,  A61K35/28

摘要： The present disclosure provides a method for preparing mesenchymal stem cell-derived extracellular vesicle, the mesenchymal stem cell-derived extracellular vesicle prepared by the method, and use of the mesenchymal stem cell-derived extracellular vesicle for reducing adipogenesis and treating osteoarthritis. The mesenchymal stem cell-derived extracellular vesicle of the present disclosure achieves the effect of reducing adipogenesis and treating osteoarthritis through various efficacy experiments.

公开(公告)号：US20240115618A1

公开(公告)日：2024-04-11

申请号：US18481041

申请日：2023-10-04

申请人： Wayne Gregory Kimpton ,  Simon Reeves Bailey ,  Silviu Itescu ,  Peter Ghosh

发明人： Wayne Gregory Kimpton ,  Simon Reeves Bailey ,  Silviu Itescu ,  Peter Ghosh

IPC分类号： A61K35/28 ,  A61K9/00 ,  A61K31/7028 ,  C12N5/0775

CPC分类号： A61K35/28 ,  A61K9/0019 ,  A61K31/7028 ,  C12N5/0663

摘要： The present disclosure provides a method for treating or preventing endothelial dysfunction in a subject, the method comprising systemically administering to the subject a population of population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.

公开(公告)号：US11952589B2

公开(公告)日：2024-04-09

申请号：US18329455

申请日：2023-06-05

申请人： Orbsen Therapeutics Limited

发明人： Stephen J. Elliman

IPC分类号： C12N5/0775 ,  A61K9/00 ,  A61K35/28 ,  A61K35/407 ,  C12N5/074 ,  C12N5/077 ,  C12Q1/37 ,  G01N33/50

CPC分类号： C12N5/0662 ,  A61K9/0019 ,  A61K35/28 ,  A61K35/407 ,  C12N5/0607 ,  C12N5/0663 ,  C12N5/0669 ,  C12Q1/37 ,  G01N33/5005

摘要： Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.

公开(公告)号：US11946070B2

公开(公告)日：2024-04-02

申请号：US17054939

申请日：2020-07-15

申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

发明人： Duk Lyul Na ,  Jong Wook Chang ,  Hyo Jin Son

IPC分类号： C12N5/0735 ,  A61K35/51 ,  A61K35/545 ,  A61P25/28 ,  A61P29/00 ,  C12N5/0775

CPC分类号： C12N5/0606 ,  A61K35/51 ,  A61K35/545 ,  A61P25/28 ,  A61P29/00 ,  C12N5/0665 ,  C12N2501/999

摘要： The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.

公开(公告)号：US11932875B2

公开(公告)日：2024-03-19

申请号：US16869208

申请日：2020-05-07

申请人： The Aerospace Corporation

发明人： Frank Edward Livingston ,  Timothy Ganey

IPC分类号： C12N5/0775 ,  B23K26/0622

CPC分类号： C12N5/0662 ,  B23K26/0622 ,  C12N2529/10 ,  C12N2533/90

摘要： A method of stimulating and controlling stem cell activity and differentiation on a modified material substrate and a device including the modified material substrate are provided. The method includes providing a material substrate configured for medical use. The material substrate includes at least one surface or interior area available for modification, and the at least one surface or interior area is treated with a plurality of pulsed light beams to obtain a modified material substrate with at least one modified surface or interior area. The at least one modified surface or interior area has a biomimetic architecture with surface and bulk (interior) features, properties, and textures configured to accelerate and control stem cell differentiation when the modified material substrate is contacted with stem cells.

公开(公告)号：US11930808B2

公开(公告)日：2024-03-19

申请号：US17276340

申请日：2019-09-18

申请人： CITOSPIN, S.L. ,  UNIVERSIDAD DE VALLADOLID

发明人： Ana Sánchez García ,  Francisco Javier García-Sancho Martín ,  Verónica García Díaz ,  Mercedes Alberca Zaballos ,  Sandra Güemes Gutiérrez

IPC分类号： A01N1/02 ,  A61K35/28 ,  C12N5/0775

CPC分类号： A01N1/0221 ,  A01N1/0226 ,  A61K35/28 ,  C12N5/0663

摘要： A method to obtain a composition comprising an enriched population of functional mesenchymal stem cells for hypothermic transport and local administration of said enriched population of functional mesenchymal stem cells in therapy. Finally also described is the use of said enriched population of functional mesenchymal stem cells, and compositions comprising them, obtained by the described method, in autologous or allogeneic treatment of diseases susceptible to mesenchymal stem cell therapy, either by local or systemic treatments, and more particularly in the treatment of osteoarticular diseases such as degenerative disc disease, osteoarthritis, and bone repair; in lupus erythematosus, graft-versus-host disease, and other autoimmune diseases; in peripheral vascular insufficiency and other cardiovascular diseases.

公开(公告)号：US20240066150A1

公开(公告)日：2024-02-29

申请号：US18466575

申请日：2023-09-13

申请人： Vertex Phamaceuticals Incorporated

发明人： Ante Sven Lundberg ,  Samarth Kulkarni ,  Lawrence Klein ,  Hari Kumar Padmanabhan

IPC分类号： A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K35/30 ,  A61P43/00 ,  C07K14/705 ,  C12N5/0775 ,  C12N5/0793 ,  C12N9/22 ,  C12N15/113 ,  C12N15/90

CPC分类号： A61K48/0066 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/51 ,  A61K35/30 ,  A61P43/00 ,  C07K14/705 ,  C12N5/0619 ,  C12N5/0663 ,  C12N9/22 ,  C12N15/1138 ,  C12N15/907 ,  C12N2310/20

摘要： The present application provides materials and methods for treating a patient with one or more conditions associated with SCN10A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN10A gene in a cell by genome editing.